Based in Mortágua, Portugal, Laboratórios Basi produces tens of millions of pharmaceutical products every year for 60 national markets worldwide. With EU financing, the company is preparing to build a new production facility that will create more than 100 jobs.
Laboratórios Basi started out in Mortágua in 1956 with the aim of developing, manufacturing and marketing drugs and therapeutic products using state-of-the-art technology.
In 2007, when it moved to the industrial park in the municipality, the company became part of the FHC Farmacêutica group.
Five years later, in 2012, Laboratórios Basi took a major step forward by setting up a quality control laboratory and building a new production facility.
The production facility is the fruit of a €15-million investment and has the capacity to produce 45 million units a year, thus helping to consolidate the company’s international position. Laboratórios Basi has a presence in 60 markets, notably in Portuguese-speaking countries in Africa, and is an important reference point within the European pharmaceutical industry.
For the future, the plan is to create 109 new jobs in the Viseu district, in which Mortágua is situated, through the implementation of an industrial project related to the production of parenteral solutions in large and small volumes. Parenteral solutions are drugs that are administered non-orally, often by way of injection directly into the body.
The project is backed by investments worth around €40 million of which funding from the EU accounts for €20 million. This will enable Laboratórios Basi to build another new facility for the manufacture of medicinal products, in particular parenteral solutions.
The award of the funding is the first time that a Portuguese mid-cap company has received support under the EU’s Investment Plan for Europe, also known as the Juncker Plan.